Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding trial
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Ponatinib (Primary) ; Antineoplastics
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms MATCHPOINT
- 03 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Dec 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network record.
- 14 Sep 2015 Accrual to date is 13% according to United Kingdom Clinical Research Network record.